Patent details

301190 Product Name: Een combinatie van rilpivirine of een door het basisoctrooi beschermde therapeutisch equivalente vorm daarvan, zoals een farmaceutisch aanvaardbaar additiezout van rilpivirine, met inbegrip van het hydrochloride-zout van rilpivirine, en emtricitabine.

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Basic Information

Publication number:
301190
Type:
Certificate
SPC Type:
Medical
Basic Patent Number:
EP3808743
Status:
Application Pending
Application number:
301190
Procedural language:
Dutch
First Applicant Residence Country:
Belgium (BE)

Marketing Authorization

Marketing Authorization Number:
EU/1/11/737/001-002
Marketing Authorization Type:
EEA
Marketing Authorization Date:
28/11/2011
Marketing Authorization Country:
European Union (EU)

Dates

Filing date:
29/07/2022
First Marketing Authorization date:
28/11/2011
Grant date:
Activation date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Registration date:
29/07/2022
SPC/SPC Extension Expiration Date:
Lapsed By Expiration Date:
Withdrawal date:
Revocation Date:
Invalidity Date:
Withdrawal Market Authorization Date:
Refusal Date:

Applicant/holder

From:
29/07/2022
 
 

 

Name:
Janssen Pharmaceutica NV
Address:
Turnhoutseweg 30, 2340 Beerse, Belgium (BE)

Agent

Name:
ir. F.A. Geurts c.s.
From:
29/07/2022
Address:
Octrooibureau Vriesendorp & Gaade B.V. Koninginnegracht 19, 2514 AB, Den Haag, Netherlands (NL)
To:

Publication

Bulletin

Bulletin Heading:
SPC
Journal edition number:
31/22
Publication date:
03/08/2022
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
Filing date Document type Document Description Number of pages File Type
17/10/2022 Incoming Correspondence Paper Accompanying letter incoming document 1 PDF /3/8/5/0/1/0800810583/docs/301190_8_incomingcorrespondencepaper20221017022253344.pdf
04/08/2022 Outgoing Correspondence Letter to applicant 3 PDF /3/8/5/0/1/0800810583/docs/301190_0_496688l173.pdf
01/08/2022 Outgoing Correspondence Confirmation receipt request 1 PDF /3/8/5/0/1/0800810583/docs/301190_1_496304l174.pdf
29/07/2022 Application Form First filed application form 4 PDF /3/8/5/0/1/0800810583/docs/301190_2_applicationform20220729043142882.pdf
29/07/2022 SPC Documents Marketing Authorization SPC 4 PDF /3/8/5/0/1/0800810583/docs/301190_3_supplprotectioncertificate20220729043240753.pdf
29/07/2022 SPC Documents Summary of the characteristics of the product 33 PDF /3/8/5/0/1/0800810583/docs/301190_4_supplprotectioncertificate20220729043357806.pdf
29/07/2022 SPC Documents Annex SPC 1 PDF /3/8/5/0/1/0800810583/docs/301190_5_supplprotectioncertificate20220729043433352.pdf
29/07/2022 SPC Documents Accompanying letter SPC 3 PDF /3/8/5/0/1/0800810583/docs/301190_6_supplprotectioncertificate20220729043614682.pdf
29/07/2022 SPC Documents Annex SPC 10 PDF /3/8/5/0/1/0800810583/docs/301190_7_supplprotectioncertificate20220729043521950.pdf